BreStem Therapeutics, Inc.

We are leading the lung regeneration revolution with diverse product platforms encompassing cell therapy, bioengineering, and smart nanotechnology providing us with the potential to treat -and hopefully cure- a broad range of serious life threatening diseases. BreStem's objective is to develop and bring to market the most advanced product based on the transformative potential of cellular and acellular therapy utilizing Lung Spheroid Cells as a treatment option for individuals living with pulmonary fibrosis. Many lung diseases such as idiopathic pulmonary fibrosis (IPF) are chronic and ultimately fatal, with no current cure. BreStem's pipeline of revolutionary products provides any patient with the hope of a better life in the face of limited options and no effective therapies. Led by a world-class leadership team with more than 40+ years experience in respiratory research and bioengineering, we are developing a diverse pipeline of patient-specific cells therapy as well as "off-the-shelf" ready stem cell product with the goal of delivering readily available cell-free therapies faster, more reliably and at greater scale to more patients around the world. The company’s lead candidate BRS101(autologous lung spheroid cells) has gained FDA approval as the world’s first IND using intrinsic lung-derived cells to treat pulmonary conditions. The company’s second candidate BRS201 (lung spheroid secretome/exosome) is currently at the preIND development stage. We are devoted to transforming the lives of patients with respiratory diseases and their families.